Pfizer (PFE) › Analysis

Pfizer (PFE) stock analysis, November 3, 2026: Raised guidance meets selling; weekly uptrend still intact

Published November 3, 2026 · updated 2026-11-13 · PFE chart, levels and live analysis

Update, November 13, 2026

Pfizer (PFE) slipped to $28.70, down 2.35% over the past five days while the S&P 500 rose 2.04% and the XLV health‑care ETF gained 1.88%, indicating a relative weakness that stems from the stock itself rather than the broader market.

The picture holds – the pullback remains within the weekly uptrend and the key swing‑zone levels are still intact. The price is now just below the 28.75 swing‑zone resistance and above the 27.8 swing‑zone support, keeping the breakout math unchanged (stop at 27.6, targets 29.21 and 30.79). A weekly close below the 28.64 SMA‑50 would be the trigger that could change the picture.

Recent headlines add nuance: Reuters reported Pfizer’s decision to cease Premarin sales in Canada, while a series of Nasdaq stories detailed a $1.5 billion co‑funding deal with Blackstone for the obesity drug berobenatide. These events are product‑specific and financing‑related and do not yet alter the technical outlook.

Pfizer Inc. (PFE) raised its full-year guidance on November 3, 2026, yet the stock slipped 2.2% to $29.995, just under the $30 round number, a day after a 52-week high of $30.67. The balance of evidence for the next two to six weeks leans positive, with medium conviction. The daily trend runs with the weekly uptrend and PFE is leading the S&P 500. A lag behind its sector and thin reward-to-risk keep conviction from going higher.

Why it matters

The news was good on guidance and mixed underneath. Pfizer lifted its full-year sales outlook to $62–64 billion from $60.5–62.5 billion and adjusted EPS to $2.95–3.05 from $2.80–3.00, crediting 32% growth in recently launched and acquired products such as Padcev and Lorbrena, Morningstar reported. Third-quarter sales of $16.58 billion were flat year over year, with a 7% rise in non-Covid medicines offset by a 29% fall in Comirnaty and a 63% drop in Paxlovid, according to the Financial Times. The 10-Q shows net income down 8% to $3.24 billion and diluted EPS down 10% to $0.56. The raise says the new products are carrying the load. The quarter itself shows no growth.

The market's response was to sell. The stock had gained 8.7% over the past month and 21.3% so far this year, and it set its 52-week high on November 2. On the day it fell 2.2% while the S&P 500 rose 0.2% and the healthcare sector ETF (XLV) slipped 0.2%, so the drop was the stock's own. None of the coverage explains it. The likeliest reason is that the raise was already in the price, but that is an inference, not a documented cause. Over five days the market was a drag: the stock rose 1.4% while the S&P 500 fell 2.1%. The sector did the heavy lifting with a 2.8% gain, leaving PFE 1.5 points behind it. The wider backdrop was cautious, with Morningstar citing nerves ahead of the U.S. midterms and a rebound in oil after strikes on Iran.

The argument about PFE is mostly about the dividend and the turnaround. The bulls point to a stock up about 20% this year with a forward yield near 5.8%, which The Motley Fool asks whether is a real turnaround. Another piece argues the shares are cheap at 9.6 times forward earnings with a 5.6% yield, NASDAQ says. The bears say the yield is high for the wrong reason. Yahoo! Finance lists Pfizer among yields that may not be sustainable because of underlying financial weakness. Flat revenue and falling EPS this quarter give that side something to point to, and the 10-year Treasury yield, at 4.958% according to PR Newswire, offers a competing income source.

Valuation leaves the stock a little ahead of the Street. Of 26 analysts, the consensus is buy, but the mean price target of $29.26 sits below the current price, which is 2.5% above it. Targets run from $25 to $36, so the spread is wide. The shares have moved past the average analyst, and the high end of the range is what supports further gains.

What the evidence says

The long-term thesis is intact. The price is above its 40-week average, the 50-day average at $28.64 is above the 200-day at $26.84, and the stock is up 14.8% over six months. It sits 26.7% above its 52-week low of $23.67 and 2.2% below its high. That points to a mature, extended uptrend that is pausing near the top of its range, not one that is rolling over.

For the next two to six weeks the balance of evidence leans positive, with medium conviction, two of four points. The daily trend runs with the weekly uptrend, and over 50 days PFE leads the S&P 500 by 6.6 points. The RSI of 58 shows the stock is neither stretched nor oversold. The strongest case against is relative performance and price. PFE trails XLV by 1.9 points over 50 days, which runs against the trend, and it lost 1.5 points to the sector this week. It also fell 2.2% on a guidance raise, and it trades above the mean analyst target. Those facts are why conviction is only medium. They do not tip the balance because no key support has broken and the longer trend measures still point up.

Levels that matter

The structure holds above $28.85, a swing zone. Just below sits the 50-day average at $28.64, the level where the trend would end. The two sit almost on top of each other, so a break of that area would take out both the recent swing low and the average that has guided the move. Below them, support is at $27.80, $27.19 and the 200-day at $26.84.

The breakout level is a daily close above $30.00, a round number, on volume above its 20-day average. Volume today is only 4.2% above that average, so the stock has not yet shown real participation. From $30.00 the first target is the 52-week high of $30.67, against a stop at $28.69, which is the $28.85 swing zone less a quarter of the 14-day average true range. That gives 0.5 to 1, far short of the 3 to 1 that makes a breakout worth the risk. Only the $35 round number, well beyond the year's high, would lift the math past 3 to 1.

What would change the picture

A weekly close below $28.64, the 50-day average, would change the picture. The non-price fact that could do it is a cut to the newly raised $62–64 billion sales guidance, which would undercut the claim that new products can offset the Covid decline. A dividend cut would hit the argument the bulls lean on.

What to watch

Get a message when the PFE picture changes — the agent team watches the levels and the news for you.Create a free account

More PFE analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.